Chest
Original ResearchCystic FibrosisEffect of Albuterol on Maximal Exercise Capacity in Cystic Fibrosis
Section snippets
Subjects
Adults with CF previously diagnosed on standard clinical and laboratory criteria were recruited from the adult CF clinic at the Mater Adult Hospital, a regional specialist CF clinic in Australia. All subjects were ≥ 16 years of age and provided written informed consent. The protocol was approved by the Local Regional Ethics Committee.
Subjects with CF were included in the study if they had been clinically stable for at least 21 days and had received no supplemental antibiotic therapy over that
Results
Twenty-two adult CF subjects were enrolled and randomized, and 20 subjects completed the study. One subject declined to participate following enrollment, and a second subject did not complete the second exercise test for personal reasons. Data from both of these were excluded. Three subjects did not perform bronchoprovocation testing, and only seven subjects completed full Borg scores during the tests. Ten subjects received albuterol first, and 10 received placebo first. Baseline
Discussion
The current study demonstrates that inhaled albuterol does not improve indexes of maximal exercise performance in CF subjects with moderate severity airways obstruction, despite causing significant acute bronchodilation. This lack of benefit persisted when only subgroups with positive bronchoprovocation test results, significant acute bronchodilator reversibility, or ventilatory limitation to exercise were considered. Furthermore, these findings are consistent with those reported by Dodd et al22
ACKNOWLEDGMENT
We are sincerely grateful to the CF patients who so willingly donated their time and effort to be involved in this study.
References (38)
Effect of β-adrenergic agonists on mucociliary clearance
J Allergy Clin Immunol
(2002)- et al.
Reduced effect of inhaled β2-adrenergic agonists on lung mucociliary clearance in patients with cystic fibrosis
Chest
(1993) - et al.
Longitudinal determinants of peak aerobic performance in children with cystic fibrosis
Chest
(2003) - et al.
A systematic review of the effects of bronchodilators on exercise capacity in patients with COPD
Chest
(2002) - et al.
Inhaled β-agonists improve lung function but not maximal exercise capacity in cystic fibrosis
J Cyst Fibros
(2005) - et al.
A controlled trial of long-term bronchodilator therapy in cystic fibrosis
Chest
(1991) - et al.
Reproducibility of maximal exercise ergometer testing in patients with cystic fibrosis
Chest
(1999) - et al.
Emerging concepts in the evaluation of ventilatory limitation during exercise
Chest
(1999) - et al.
Ventilation-perfusion response after fenoterol in hypoxemic patients with stable COPD
Chest
(1996) - et al.
International practice patterns by age and severity of lung disease in cystic fibrosis: data from the epidemiologic registry of cystic fibrosis (ERCF)
Pediatr Pulmonol
(1997)
“CF asthma”: what is it and what can we do about it?
Thorax
Atopy and bronchial reactivity in older patients with cystic fibrosis
Thorax
Bronchodilators in cystic fibrosis
J R Soc Med
A longitudinal study of bronchodilator responsiveness in cystic fibrosis
Am Rev Respir Dis
Bronchodilators increase airway instability in cystic fibrosis
Am Rev Respir Dis
Nonhomogeneous lung emptying in cystic fibrosis patients
Am Rev Respir Dis
The prognostic value of exercise testing in patients with cystic fibrosis
N Engl J Med
Determinants of aerobic and anaerobic exercise performance in cystic fibrosis
Am J Respir Crit Care Med
Peripheral muscle weakness and exercise capacity in children with cystic fibrosis
Am J Respir Crit Care Med
Cited by (0)
This work was performed at Mater Adult Hospital, South Brisbane, Australia.
The authors have no conflicts of interest to disclose.